Lynda Maxfield
Psychiatric/Mental Health · Clio, MINPI 1932654753
Payments from drug & device makers
Across 141 payments — averaging $23.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$665
- Neurocrine Biosciences, Inc.$609
- Alkermes, Inc.$596
- AbbVie$299
- Otsuka America Pharmaceutical, Inc.$237
- Indivior Inc.$219
- plus $712 from 13 others
What the payments were for
- Food & beverage$3,337100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 22 | $665 |
| Neurocrine Biosciences, Inc. | 31 | $609 |
| Alkermes, Inc. | 22 | $596 |
| AbbVie | 15 | $299 |
| Otsuka America Pharmaceutical, Inc. | 9 | $237 |
| Indivior Inc. | 10 | $219 |
| Novartis | 9 | $201 |
| Vanda Pharmaceuticals Inc. | 5 | $139 |
| Exact Sciences | 4 | $99 |
| Axsome Therapeutics, Inc. | 3 | $75 |
| Teva Pharmaceuticals USA, Inc. | 2 | $34 |
| Novo Nordisk | 2 | $34 |
| Pfizer | 1 | $26 |
| Lundbeck LLC | 1 | $21 |
| GSK | 1 | $20 |
| Braeburn Inc. | 1 | $18 |
| Cipher Pharmaceuticals US LLC | 1 | $16 |
| Pear Therapeutics (US), Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,337 in reported general payments places this provider in the 80th percentile of 638 psychiatric/mental health providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VivitrolNaltrexone Microspheres | 12 | $20,072 |
| OzempicSemaglutide | 13 | $11,783 |
| XareltoRivaroxaban | 17 | $9,440 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 25 | $711 |
| Ventolin HfaAlbuterol Sulfate | 12 | $680 |
| Omeprazole | 41 | $622 |
| Atorvastatin Calcium | 48 | $508 |
| Naltrexone Hcl | 16 | $507 |
| Amlodipine Besylate | 47 | $353 |
| Lisinopril | 55 | $343 |
| Spironolactone | 13 | $258 |
| Ibuprofen | 19 | $198 |
| Gabapentin | 21 | $187 |
| Levothyroxine Sodium | 15 | $156 |
| Metformin Hcl | 33 | $119 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Alkermes, Inc.Vivitrol | $596 | $20,07212 claims |
| Novo NordiskOzempic | $34 | $11,78313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 638 psychiatric/mental health providers in Michigan.
Other psychiatric/mental health in Clio
- Duren GutierrezSouthfield$207K
- Tamlynn EvansTraverse City$78K
- Shiba NixonClarkston$60K
- Amy AmesClinton Township$43K
- Cody ShinavierClarkston$41K
- Oksana LidkeBattle Creek$30K
- Jennifer Wims-MaddenPontiac$28K
- Jessica ShantzWarren$21K
- Gladys KimeliSaginaw$17K
- Cynthia MaiSaginaw$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.